Cancer statistics, 2022
2022/01/01 by Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs +1 · 1 voice · 86 citations
Economics, Econometrics and Finance · Medicine · #Cancer Risks and Factors #Economic and Financial Impacts of Cancer #Global Cancer Incidence and Screening
paper · pdf · doi:10.3322/caac.21708
openalex publication_date 2022/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.
Citations
Cited by
- Cancer statistics, 2023
- Cancer treatment and survivorship statistics, 2022
- Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
- Breast Cancer Statistics, 2022
- Cancer statistics for African American/Black People 2022
- Cancer statistics for A merican I ndian and A laska N ative individuals, 2022: Including increasing disparities in early onset colorectal cancer
- CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
- Epidemiology of Cancer
- Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
- Endoscopic submucosal dissection with versus without traction for pathologically staged T1B esophageal cancer: a multicenter retrospective study
- MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2
- Optimal policy tree to assist in adjuvant therapy decision-making after resection of colorectal liver metastases
- Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer
- 3D multi‐view squeeze‐and‐excitation convolutional neural network for lung nodule classification
- Defining the tumor microenvironment of non‐small cell lung cancer
- Initial Results and Clinical Experiences of [ 177 Lu]Lu-FAP-2286 for Pleural Metastases: A Single-Center Retrospective Study
- Characterizing the Impact of Training Data on Generalizability: Application in Deep Learning to Estimate Lung Nodule Malignancy Risk
- Concordance Between Trainee Self-Assessment and Expert Assessment of Cold Snare Polypectomy Competence: Results From a Randomized Clinical Study
- Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial
- Anti-inflammatory efficacy of diosgenin in an oxazolone-induced model of ulcerative colitis in mice via suppression of Th2 pathways and pSTAT3 expression: A prospective study
- Co-targeting autophagy and NRF2 signaling triggers mitochondrial superoxide to sensitize oral cancer stem cells for cisplatin-induced apoptosis
- Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
- Pyridoxal Reprograms Peroxisomal Hydrogen Peroxide Metabolism to Induce Lethal Oxidative Stress in Ovarian Cancer
- Region of Interest Detection in Melanocytic Skin Tumor Whole Slide Images -- Nevus & Melanoma
- Cancer statistics in China and United States, 2022: profiles, trends, and determinants
- EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer
- FOXM1: A small fox that makes more tracks for cancer progression and metastasis
- Ferrite/curcumin hybrid nanocomposite formulation: Physicochemical characterization, anticancer activity, and apoptotic and cell cycle analyses in skin cancer cells
- Colorectal cancer molecular profiling: Opportunities for early detection
- 3D genomic mapping reveals multifocality of human pancreatic precancers
- Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort
- Activation of Hedgehog pathway by circEEF2/miR-625-5p/TRPM2 axis promotes prostate cancer cell proliferation through mitochondrial stress
- Impact of postoperative complications and type 2 diabetes on breast cancer recurrence and mortality
- The microbial landscape of colorectal cancer
- Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress
- Prediction of heart failure and all-cause mortality using cardiac ultrasomics in patients with breast cancer
- Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy
- Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression
- Incorporating external risk information with the Cox model under population heterogeneity: applications to trans-ancestry polygenic hazard scores
- A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes
- Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer
- Multi-Scale Deep Learning for Colon Histopathology: A Hybrid Graph-Transformer Approach
- Vitamin D delivered through carbon quantum dots modifies cytokine expression and migration in MCF-7 breast cancer cells
- Precision Oncology: Targeting Genomic Alterations and Cancer Signaling with Integrative Multi-Omics, Deep Learning and Network Biology in Medical Oncology
- Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing
- Advanced Deep Learning Techniques for Accurate Lung Cancer Detection and Classification
- Advanced Multi-Architecture Deep Learning Framework for BIRADS-Based Mammographic Image Retrieval: Comprehensive Performance Analysis with Super-Ensemble Optimization
- Global cancer mortality among children, adolescents, and young adults from 77 countries, 1990–2021: a global time-series analysis and modelling study
- Identification of Molecular Biomarkers of Diffuse Large B-Cell Lymphoma Through Gold Nanoparticle-Based Surface-Enhanced Raman Spectroscopy (SERS) Coupled with Multivariate Analysis
- Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer
- Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway
- Hsa-miR-181a-2-3p inhibits the oncogenicity of colon cancer by directly targeting STING
- Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells
- Challenges and Advantages of Using Spatially Resolved Lipidomics to Assess the Pathological State of Human Lung Tissue
- 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer
- Clinical applications of deep learning in breast MRI
- Standard-definition White-light, High-definition White-light versus Narrow-band Imaging Endoscopy for Detecting Colorectal Adenomas: A Multicenter Randomized Controlled Trial
- Assessing the assessment: a scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials
- Epidemiology of Renal Cell Carcinoma: 2022 Update
- What’s missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials
- Patient Out‐of‐Pocket Costs and Healthcare Utilization Related to Mastectomy vs Breast Conservation: A Claims‐Based Study
- Cancer statistics in China and United States, 2022: profiles, trends, and determinants. [europepmc]
- Natural killer cell homing and trafficking in tissues and tumors: from biology to application. [europepmc]
- Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. [europepmc]
- Non-small cell lung cancer in China. [europepmc]
- Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. [europepmc]
- Annual report to the nation on the status of cancer, part 1: National cancer statistics. [europepmc]
- Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. [europepmc]
- Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. [europepmc]
- Biology, vulnerabilities and clinical applications of circulating tumour cells. [europepmc]
- Liquid biopsies: the future of cancer early detection. [europepmc]
- Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. [europepmc]
- Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. [europepmc]
- Lung cancer immunotherapy: progress, pitfalls, and promises. [europepmc]
- Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. [europepmc]
- Activated fibroblasts in cancer: Perspectives and challenges. [europepmc]
- Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers. [europepmc]
- Metastasis. [europepmc]
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. [europepmc]
- Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8 + T cells. [europepmc]
- Principles and methods for transferring polygenic risk scores across global populations. [europepmc]
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. [europepmc]
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. [europepmc]
- Bladder cancer. [europepmc]
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. [europepmc]
Discussions
Related